Monday, 14 September 2026European Markets

MELHUS SPAREBANK And CRCAM BRIE PIC2CCI Have A High Dividend Yield And Return On Equity In The Financial Services Sector.

Loading stream...

(vianews) - melhus sparebank (melg.ol) is among this list of stock assets with the highest dividend rate and return on equity on the financial services sector.

financial asset price forward dividend yield return on equity
melhus sparebank (melg.ol) kr156.00 6.92% 10.56%
crcam brie pic2cci (crbp2.pa) €18.80 5.48% 3.64%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. melhus sparebank (melg.ol)

6.92% forward dividend yield and 10.56% return on equity

melhus sparebank, a savings bank, provides various banking products and services to companies, agriculture customers, and private individuals in norway. the company offers savings accounts; construction and business loans; bank guarantee, overdraft, and leasing services; and credit and bank cards. it also provides various insurance products for liability, health, personnel, occupational injury, travel, accident, business, store, data attack, property damage, craftsman, homeowners, office, vehicle, and farms; savings and pension products; payment services; and online and mobile banking services. the company operates through branch offices in central trondheim, heimdal, ler, and korsvegen. melhus sparebank was founded in 1840 and is headquartered in melhus, norway.

earnings per share

as for profitability, melhus sparebank has a trailing twelve months eps of kr16.44.

pe ratio

melhus sparebank has a trailing twelve months price to earnings ratio of 9.49. meaning, the purchaser of the share is investing kr9.49 for every norwegian krone of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.56%.

more news about melhus sparebank.

2. crcam brie pic2cci (crbp2.pa)

5.48% forward dividend yield and 3.64% return on equity

caisse régionale de crédit agricole mutuel brie picardie société coopérative provides a range of banking and financial products and services to individuals, farmers, professionals, businesses, and local authorities in france. it offers savings support comprising monetary, bonds, and securities; and life insurance investments, as well as housing and consumer loans; payment services; and property and casualty insurance, provident insurance products, and life insurance products. the company was founded in 2005 and is headquartered in amiens, france. caisse régionale de crédit agricole mutuel brie picardie société coopérative operates as a subsidiary of crédit agricole s.a.

pe ratio

crcam brie pic2cci has a trailing twelve months price to earnings ratio of 1.67. meaning, the purchaser of the share is investing €1.67 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.64%.

yearly top and bottom value

crcam brie pic2cci's stock is valued at €18.80 at 07:30 est, below its 52-week high of €20.10 and way above its 52-week low of €16.90.

more news about crcam brie pic2cci.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Keeps Flowing as Enterprise Adoption and Government Contracts Validate the Bet
A late-August surge of nine-figure funding rounds (Socure, Stability AI, Generalist AI, Gatik, Regent Craft, Emerald AI, Owner) shows venture capital still pouring into AI infrastructure, identity/fintech, and autonomy, even as public-market sentiment stays jumpy — Palantir's stock fell 6% the same week it landed the Army's TITAN contract. UiPath's raised guidance and strong Q2 results, alongside efficiency breakthroughs like Multiverse Computing's model compression, point to real enterprise monetization catching up to the funding hype.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts record the same attribute (net_income) for JPMorgan Chase & Co. in the identical fiscal period (Q1 2026) and observation date (2026-03-31), but report values that differ by approximately 1 billion times: $16,494,000,000 vs $16.49. These cannot both be true simultaneously. The discrepancy suggests either a unit mismatch (e.g., one is total net income, the other earnings per share mislabeled as net_income), a decimal point error, or data entry corruption. For the same entity, attribute, and time period, only one value can be correct.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,285 source documents archived
Query this data → isubstrate.com